The Global Meningococcal Vaccine Market size is expected to reach $4.5 billion by 2026, rising at a market growth of 8.5% CAGR during the forecast period. Meningococcal meningitis is a bacterial infection that is caused by gram-negative bacteria, Neisseria meningitides that includes a spectrum of infections such as bacteremia (meningococcemia), meningitis, and bacteremia pneumonia.
The meningococcal disease is very rare but is highly fatal, if left untreated, up to 50% of the patients die or get some serious complications thereafter. In meningococcal meningitis, bacteria infect the lining of the brain and spinal cord and can potentially cause large endemics as well as epidemics. The disease is transmitted from an infected person through direct contact with droplets of the throat or respiratory secretions, asymptomatic carriers can also capable of transmitting infection.
There is an increasing prevalence of various types of bacteria that cause meningococcal meningitis. The most common type of meningitis causing bacteria are A, B, C, W, Y, and type X that was more lately reported in Africa, continue to underline the criticality of more effective vaccine of meningococcal to be available in the coming years.
Over the past few decades, cases of meningitis have been increased and are one of the key factors likely to drive the market for meningococcal vaccines. According to the Centers for Disease Control and Prevention (CDC), about 1.2 million cases of meningococcal meningitis are estimated to occur worldwide every year. The government and regulatory authorities are taking initiatives to combat the increasing prevalence of meningitis are likely to drive the market growth. For example, “Defeating meningitis by 2030” was introduced in 2018 at the World Health Assembly by Eastern Mediterranean and African regions. This program is focused to develop a strategic roadmap for the prevention of meningitis by prioritizing research and improved control activities.
By Brand
Based on Brand, the market is segmented into Bexsero, Trumenba, Nimenrix, Menactra, Menveo and Other Brands. The MenACWY vaccine and MenC vaccine are expected to experience swift growth during the forecast period. This is accredited to the increased adoption of these vaccines in several countries across the globe through immunization programs. Furthermore, outbreaks of meningococcal in several countries resulted in an increasing demand for meningococcal vaccines, which further boost the growth of the meningococcal vaccine market.
By Type
Based on Type, the market is segmented into Bivalent, Quadrivalent and Other Types. Quadrivalent meningococcal vaccines had the largest revenue share of the market in 2019, owing to the increased used brands like Menveo, Menactra, and Nimenrix, for this category. New vaccines are increasingly approved that will protect people against meningococcal meningitis and is expected to boost the growth of this market.
By Age Group
Based on Age Group, the market is segmented into Infants (0 to 2 years) and Children (2 years & above). The infant segment is anticipated to be the fastest-growing segment in the coming years due to the increasing incidence of meningitis among infants. According to the European Centre for Disease Prevention and Control (ECDC), IMD incidence was observed highest in infants in 2017. In Europe, there were nearly 8.2 confirmed cases per 100,000 populations in children below one year.
By Region
Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. North America led the market and had a significant revenue share of the market in 2019 which is followed by Europe. Favorable approvals, supportive initiatives by the government, and high investments in R&D are the major factors fueling the North American market.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include GlaxoSmithKline PLC (GSK), Pfizer, Inc., Sanofi S.A., Walvax Biotechnology Co., Ltd., Bio-Manguinhos (Oswaldo Cruz Foundation), Bio-Med Pvt. Ltd., Chongqing Zhifei Biological Products Co., Ltd., Hualan Biological Engineering, Inc., Incepta Pharmaceuticals Ltd. and Serum Institute of India Pvt. Ltd. (Poonawalla Investments & Industries Pvt. Ltd.).
Strategies deployed in Meningococcal Vaccine Market
Dec-2020: Serum Institute of India (SII) launched world's most affordable pneumococcal conjugate vaccine (PCV) in India. This vaccine provides protection against 10 variants of pneumococcus bacteria that causes pneumonia, meningitis, ear, and blood infections in children.
Dec-2020: The Oswaldo Cruz Foundation, through the Institute of Technology in Immunobiologicals (Bio-Manguinhos) announced an agreement with the Government of the State of Rio de Janerio. Following this agreement, the Industrial Complex of Biotechnology in Health (Cibs) will be built, in the Industrial District of Santa Cruz, in Rio de Janeiro. The new plant aims to enable the production of new vaccines, such as the bivalent vaccine (measles and rubella), clinical studies of which were recently concluded by Bio-Manguinhos, and meningococcal C, which is in an advanced stage of studies phases II/III, in addition to new vaccine presentations from the Institute's portfolio (number of doses/bottle), to meet different needs of the health system.
Nov-2020: Sanofi's MenQuadfi received approval from The European Commission (EC) for active immunization of individuals from the age of 12 months and older against invasive meningococcal disease. This disease is caused by Neisseria meningitidis serogroups A, C, W and Y. The MenQuadfi has been delivering optimized stability while maintaining the vaccine in a convenient, fully liquid presentation. Apr-2018: Pfizer's TRUMENBA (Meningococcal Group B Vaccine) received approval from the U.S. Food and Drug Administration (FDA). This vaccine is being used for active immunization for preventing invasive disease caused by Neisseria meningitidis group B (MenB) in children ages 1 through 9 years.
Apr-2020: MenQuadfi, Meningococcal (Groups A, C, Y, W) Conjugate Vaccine received Biologics License Application approval from FDA. This vaccine has been used for the prevention of invasive meningococcal disease in persons 2 years of age and older.
Feb-2018: GlaxoSmithKline announced that it received Breakthrough Therapy Designation from FDA for its meningitis B vaccine Bexsero for developing vaccine in the prevention of Invasive Meningococcal Disease (IMD) caused by serogroup B in children 2-10 years of age.
May-2017: Pfizer announced that European Commission approved TRUMENBA (Meningococcal Group B Vaccine). This vaccine aimed to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B (MenB) in individuals 10 years of age and older.
Dec-2016: Pfizer got approval from European Commission for Nimenrix (meningococcal group A, C, W-135, and Y conjugate vaccine). This vaccine was developed for active immunization against invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroups A, C, W-135, and Y (MenACWY) in infants as early as six weeks of age.
Scope of the Study
Market Segments covered in the Report:
By Brand
By Type
By Age Group
By Geography
Companies Profiled
Unique Offerings from the Publisher
The meningococcal disease is very rare but is highly fatal, if left untreated, up to 50% of the patients die or get some serious complications thereafter. In meningococcal meningitis, bacteria infect the lining of the brain and spinal cord and can potentially cause large endemics as well as epidemics. The disease is transmitted from an infected person through direct contact with droplets of the throat or respiratory secretions, asymptomatic carriers can also capable of transmitting infection.
There is an increasing prevalence of various types of bacteria that cause meningococcal meningitis. The most common type of meningitis causing bacteria are A, B, C, W, Y, and type X that was more lately reported in Africa, continue to underline the criticality of more effective vaccine of meningococcal to be available in the coming years.
Over the past few decades, cases of meningitis have been increased and are one of the key factors likely to drive the market for meningococcal vaccines. According to the Centers for Disease Control and Prevention (CDC), about 1.2 million cases of meningococcal meningitis are estimated to occur worldwide every year. The government and regulatory authorities are taking initiatives to combat the increasing prevalence of meningitis are likely to drive the market growth. For example, “Defeating meningitis by 2030” was introduced in 2018 at the World Health Assembly by Eastern Mediterranean and African regions. This program is focused to develop a strategic roadmap for the prevention of meningitis by prioritizing research and improved control activities.
By Brand
Based on Brand, the market is segmented into Bexsero, Trumenba, Nimenrix, Menactra, Menveo and Other Brands. The MenACWY vaccine and MenC vaccine are expected to experience swift growth during the forecast period. This is accredited to the increased adoption of these vaccines in several countries across the globe through immunization programs. Furthermore, outbreaks of meningococcal in several countries resulted in an increasing demand for meningococcal vaccines, which further boost the growth of the meningococcal vaccine market.
By Type
Based on Type, the market is segmented into Bivalent, Quadrivalent and Other Types. Quadrivalent meningococcal vaccines had the largest revenue share of the market in 2019, owing to the increased used brands like Menveo, Menactra, and Nimenrix, for this category. New vaccines are increasingly approved that will protect people against meningococcal meningitis and is expected to boost the growth of this market.
By Age Group
Based on Age Group, the market is segmented into Infants (0 to 2 years) and Children (2 years & above). The infant segment is anticipated to be the fastest-growing segment in the coming years due to the increasing incidence of meningitis among infants. According to the European Centre for Disease Prevention and Control (ECDC), IMD incidence was observed highest in infants in 2017. In Europe, there were nearly 8.2 confirmed cases per 100,000 populations in children below one year.
By Region
Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. North America led the market and had a significant revenue share of the market in 2019 which is followed by Europe. Favorable approvals, supportive initiatives by the government, and high investments in R&D are the major factors fueling the North American market.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include GlaxoSmithKline PLC (GSK), Pfizer, Inc., Sanofi S.A., Walvax Biotechnology Co., Ltd., Bio-Manguinhos (Oswaldo Cruz Foundation), Bio-Med Pvt. Ltd., Chongqing Zhifei Biological Products Co., Ltd., Hualan Biological Engineering, Inc., Incepta Pharmaceuticals Ltd. and Serum Institute of India Pvt. Ltd. (Poonawalla Investments & Industries Pvt. Ltd.).
Strategies deployed in Meningococcal Vaccine Market
Dec-2020: Serum Institute of India (SII) launched world's most affordable pneumococcal conjugate vaccine (PCV) in India. This vaccine provides protection against 10 variants of pneumococcus bacteria that causes pneumonia, meningitis, ear, and blood infections in children.
Dec-2020: The Oswaldo Cruz Foundation, through the Institute of Technology in Immunobiologicals (Bio-Manguinhos) announced an agreement with the Government of the State of Rio de Janerio. Following this agreement, the Industrial Complex of Biotechnology in Health (Cibs) will be built, in the Industrial District of Santa Cruz, in Rio de Janeiro. The new plant aims to enable the production of new vaccines, such as the bivalent vaccine (measles and rubella), clinical studies of which were recently concluded by Bio-Manguinhos, and meningococcal C, which is in an advanced stage of studies phases II/III, in addition to new vaccine presentations from the Institute's portfolio (number of doses/bottle), to meet different needs of the health system.
Nov-2020: Sanofi's MenQuadfi received approval from The European Commission (EC) for active immunization of individuals from the age of 12 months and older against invasive meningococcal disease. This disease is caused by Neisseria meningitidis serogroups A, C, W and Y. The MenQuadfi has been delivering optimized stability while maintaining the vaccine in a convenient, fully liquid presentation. Apr-2018: Pfizer's TRUMENBA (Meningococcal Group B Vaccine) received approval from the U.S. Food and Drug Administration (FDA). This vaccine is being used for active immunization for preventing invasive disease caused by Neisseria meningitidis group B (MenB) in children ages 1 through 9 years.
Apr-2020: MenQuadfi, Meningococcal (Groups A, C, Y, W) Conjugate Vaccine received Biologics License Application approval from FDA. This vaccine has been used for the prevention of invasive meningococcal disease in persons 2 years of age and older.
Feb-2018: GlaxoSmithKline announced that it received Breakthrough Therapy Designation from FDA for its meningitis B vaccine Bexsero for developing vaccine in the prevention of Invasive Meningococcal Disease (IMD) caused by serogroup B in children 2-10 years of age.
May-2017: Pfizer announced that European Commission approved TRUMENBA (Meningococcal Group B Vaccine). This vaccine aimed to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B (MenB) in individuals 10 years of age and older.
Dec-2016: Pfizer got approval from European Commission for Nimenrix (meningococcal group A, C, W-135, and Y conjugate vaccine). This vaccine was developed for active immunization against invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroups A, C, W-135, and Y (MenACWY) in infants as early as six weeks of age.
Scope of the Study
Market Segments covered in the Report:
By Brand
- Bexsero
- Trumenba
- Nimenrix
- Menactra
- Menveo
- Other Brands
By Type
- Bivalent
- Quadrivalent
- Other Types
By Age Group
- Infants (0 to 2 years)
- Children (2 years & above)
By Geography
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
- LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Companies Profiled
- GlaxoSmithKline PLC (GSK)
- Pfizer, Inc.
- Sanofi S.A.
- Walvax Biotechnology Co., Ltd.
- Bio-Manguinhos (Oswaldo Cruz Foundation)
- Bio-Med Pvt. Ltd.
- Chongqing Zhifei Biological Products Co., Ltd.
- Hualan Biological Engineering, Inc.
- Incepta Pharmaceuticals Ltd.
- Serum Institute of India Pvt. Ltd. (Poonawalla Investments & Industries Pvt. Ltd.)
Unique Offerings from the Publisher
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 4. Global Meningococcal Vaccine Market by Brand
Chapter 5. Global Meningococcal Vaccine Market by Type
Chapter 6. Global Meningococcal Vaccine Market by Age Group
Chapter 7. Global Meningococcal Vaccine Market by Region
Chapter 8. Company Profiles
Companies Mentioned
- GlaxoSmithKline PLC (GSK)
- Pfizer, Inc.
- Sanofi S.A.
- Walvax Biotechnology Co., Ltd.
- Bio-Manguinhos (Oswaldo Cruz Foundation)
- Bio-Med Pvt. Ltd.
- Chongqing Zhifei Biological Products Co., Ltd.
- Hualan Biological Engineering, Inc.
- Incepta Pharmaceuticals Ltd.
- Serum Institute of India Pvt. Ltd. (Poonawalla Investments & Industries Pvt. Ltd.)
Methodology
LOADING...
